Cybin (CYBN) Competitors $5.98 -0.03 (-0.50%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$5.96 -0.02 (-0.40%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CYBN vs. GHRS, KALV, KURA, SIGA, BCAX, VIR, RLAY, KROS, MGTX, and TYRAShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include GH Research (GHRS), KalVista Pharmaceuticals (KALV), Kura Oncology (KURA), Siga Technologies (SIGA), Bicara Therapeutics (BCAX), Vir Biotechnology (VIR), Relay Therapeutics (RLAY), Keros Therapeutics (KROS), MeiraGTx (MGTX), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Its Competitors GH Research KalVista Pharmaceuticals Kura Oncology Siga Technologies Bicara Therapeutics Vir Biotechnology Relay Therapeutics Keros Therapeutics MeiraGTx Tyra Biosciences GH Research (NASDAQ:GHRS) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations. Which has more risk & volatility, GHRS or CYBN? GH Research has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Do analysts recommend GHRS or CYBN? GH Research currently has a consensus target price of $32.00, suggesting a potential upside of 127.76%. Cybin has a consensus target price of $85.00, suggesting a potential upside of 1,321.40%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is GHRS or CYBN more profitable? GH Research's return on equity of -16.71% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -16.71% -16.06% Cybin N/A -37.58%-36.59% Which has higher valuation and earnings, GHRS or CYBN? GH Research is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.74-18.99CybinN/AN/A-$57.88M-$4.60-1.30 Does the media favor GHRS or CYBN? In the previous week, GH Research had 7 more articles in the media than Cybin. MarketBeat recorded 9 mentions for GH Research and 2 mentions for Cybin. GH Research's average media sentiment score of 0.81 beat Cybin's score of 0.00 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Cybin 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of GHRS or CYBN? 56.9% of GH Research shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryGH Research beats Cybin on 10 of the 14 factors compared between the two stocks. Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$141.07M$822.15M$5.76B$21.26BDividend YieldN/A4.84%6.67%3.52%P/E Ratio-1.361.0975.7529.40Price / SalesN/A26.59547.7849.02Price / CashN/A19.5637.0524.13Price / Book0.556.6411.154.54Net Income-$57.88M-$4.78M$3.29B$999.70M7 Day Performance-20.05%1.53%0.20%0.08%1 Month Performance-21.00%12.43%6.30%5.22%1 Year PerformanceN/A29.37%54.81%15.24% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin1.9136 of 5 stars$5.98-0.5%$85.00+1,321.4%N/A$141.07MN/A-1.3650Gap UpHigh Trading VolumeGHRSGH Research2.436 of 5 stars$13.18+0.8%$32.00+142.8%+65.9%$680.53MN/A-17.8110News CoverageKALVKalVista Pharmaceuticals4.0501 of 5 stars$12.99-3.1%$26.29+102.4%+17.6%$675.06MN/A-3.52100News CoverageKURAKura Oncology3.8371 of 5 stars$7.65flat$24.10+215.0%-59.0%$664M$53.88M-3.38130News CoveragePositive NewsAnalyst ForecastSIGASiga Technologies2.356 of 5 stars$8.70-4.7%N/A+8.2%$653.76M$138.72M7.7040News CoveragePositive NewsOptions VolumeBCAXBicara Therapeutics2.5936 of 5 stars$11.32-4.4%$32.25+184.9%N/A$646.03MN/A-3.5732Positive NewsVIRVir Biotechnology3.2013 of 5 stars$4.38-4.4%$30.25+590.6%-32.4%$636.24M$74.21M-1.10580News CoverageAnalyst ForecastInsider TradeRLAYRelay Therapeutics2.4032 of 5 stars$3.51-4.9%$17.25+391.5%-37.0%$636.20M$8.36M-1.80330News CoverageAnalyst ForecastGap UpKROSKeros Therapeutics3.2305 of 5 stars$14.76-5.1%$30.00+103.3%-70.6%$631.97M$232.84M47.61100News CoveragePositive NewsMGTXMeiraGTx4.5065 of 5 stars$7.58-3.2%$24.00+216.6%+95.9%$629.90M$33.28M-3.72300Positive NewsTYRATyra Biosciences2.7652 of 5 stars$12.00+2.5%$30.83+156.9%-43.0%$624.11MN/A-6.7420News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies GHRS Competitors KALV Competitors KURA Competitors SIGA Competitors BCAX Competitors VIR Competitors RLAY Competitors KROS Competitors MGTX Competitors TYRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CYBN) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
